Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alsoKnownAs |
gptkb:3-Quinuclidinyl_benzilate
|
| gptkbp:antidote |
gptkb:physostigmine
|
| gptkbp:appearance |
white crystalline solid
|
| gptkbp:CASNumber |
6581-06-2
|
| gptkbp:category |
gptkb:anticholinergic_agent
gptkb:chemical_weapon gptkb:deliriant |
| gptkbp:chemicalFormula |
C21H23NO3
|
| gptkbp:developedBy |
gptkb:Edgewood_Arsenal
|
| gptkbp:effect |
disorientation
delirium hallucinations |
| gptkbp:firstSynthesized |
1951
|
| gptkbp:legalStatus |
gptkb:Schedule_II_(USA)
|
| gptkbp:mechanismOfAction |
anticholinergic
|
| gptkbp:molecularWeight |
337.41 g/mol
|
| gptkbp:NATODesignation |
BZ
|
| gptkbp:routeOfExposure |
inhalation
skin contact |
| gptkbp:solubility |
slightly soluble in water
|
| gptkbp:toxicity |
high
|
| gptkbp:usedAs |
gptkb:incapacitating_agent
|
| gptkbp:usedBy |
gptkb:military
|
| gptkbp:bfsParent |
gptkb:Crude_oil_futures
|
| gptkbp:bfsLayer |
7
|
| http://www.w3.org/2000/01/rdf-schema#label |
BZ (ICE)
|